Shots:

• The ongoing AXO-Lenti-PD (also known OXB-102) study evaluates efficacy- safety- tolerability and measuring motor function in patients with PD. The closure of initial results from study is expected in H1’19
• The trial is based on results of P-I/II trial of ProSavin for its safety and efficacy- demonstrating reductions in UPDRS Part III “OFF” scores for up to 6yrs. and is presented at Annual Congress of ESGCT18
• AXO-Lenti-PD is a novel gene therapy allowing expression of three enzymes for dopamine synthesis in the brain. In 2018- Axovant gained rights for AXO-Lenti-PD therapy from Oxford BioMedica

/ article | Ref: Oxford Biomedica | Image: Talk markets